Tuberculosis (TB), an airborne infectious disease caused by Mycobacterium tuberculosis, spreads primarily when active in the lungs of patients with undiagnosed TB disease.^1,2 TB infectivity and transmission continue to be an on-going and challenging concern, especially in high-incidence areas, requiring facilities to have appropriate infection control plans to reduce TB spread.³ This two-part series aims to outline that balanced patient-specific infection control and patient isolation measures will also remove barriers to comprehensive TB care with its associated co-morbidities. Thus, TB should not be managed as an isolated phenomenon, as emphasized in part two of this opinion series.

Before TB treatment begins, an array of factors determining individual TB infectivity is categorized as follows:

• patient-based: infectiousness of the source case, M. tuberculosis burden, presence of cavitary disease, severity of cough, history of treatment time and adherence, drug/multidrug resistance and host susceptibility;

• exposure-based: duration, frequency and proximity; and

• environment-based: pace, concentration, ventilation and air circulation.⁴

Untreated patients with active pulmonary TB are more infectious than those receiving appropriate therapy.³ Drug-resistant strains of TB add complexity to the situation, as they are more difficult to treat and can spread from person to person; patients can continue to be contagious if they are treated for drug-sensitive TB and later found to carry a drug-resistant strain.^4,5

Various TB infection control measures have been developed based on a multi-layered approach, which includes administrative, environmental and personal respiratory protection measures implemented in healthcare settings globally to reduce the risk of TB transmission.⁶

Patients suspected of having pulmonary TB and confirmed TB cases are usually placed in isolation and are instructed to avoid public places and close contact with noninfected people to minimize the risk of community spread until active TB disease is ruled out or the patients are deemed noninfectious.⁷ There is a spectrum of isolation, from strict airborne isolation while in the hospital, to home isolation while infectious, to care in a TB-focused facility.

TB isolation has evolved significantly over time, driven by increased scientific understanding, shifts in public health strategies and an understanding of both the psychological and financial effects of isolation on patients. Currently, the optimal duration and the parameters defining patient isolation remain controversial and in flux, since the most recent update to guidelines in 2024 by the Infectious Diseases Society of America (IDSA)/National Tuberculosis Controllers Association (NTCA).⁸

With the age-old measures of isolation practices in sanatoriums, the WHO has advocated for ambulatory management/treating patients outside of a hospital setting, and, in the early 2000s, the Centers for Disease Control and Prevention (CDC), UK Department of Health and Public Health Authority, Canada made statements on discontinuation of airborne isolation after 14 days of appropriate therapy.^9,10 With the understanding that the best form of isolation is starting TB chemotherapy expeditiously, the practice of at least 2 weeks of strict respiratory isolation from the beginning of the treatment was adopted as a standard measure by many healthcare settings until:

• a patient had three consecutive negative acid-fast bacillus sputum smears, at least 8 hours apart;

• a patient had received appropriate anti-TB medication for 2 weeks;

• the patient was clinically improving; and

• the patient had plans for follow-up care.^9,11

However, when we look back at all the data collected to support this determination over the past 50 years, there is no strong data supporting this 2-week determination and need for isolation. The landmark 1960 Madras study and subsequent publications emphasized that once appropriate TB treatment was started, there was no increased risk to household contacts in a crowded home versus care in a sanatorium.^9–12

More recent transcriptome studies showed a 90% decline in TB transmission within the first 48 hours of treatment, and even more in the first 96 hours.^10,11 Seminal human-to-guinea-pig studies suggest that transmission ceases almost immediately with effective treatment.¹³ This observation has been postulated to stem from the rapid decline in bacillary load within the first 2 days of treatment, as well as from mycobacterial impairments resulting from anti-TB therapy.^12,13 The previous recommendation for a minimum 14-day isolation period plus post-isolation precautions has been removed.¹³ A systematic review of all the available data resulted in the 2024 NTCA/IDSA recommendation that airborne isolation be lifted after 5 days of appropriate therapy if a patient is at low risk for home transmission and has no vulnerable contacts.¹⁰

The current CDC approach focuses on case-to-case assessment, implementing precautions based on symptoms and transmission risk rather than relying on a fixed isolation or quarantine duration.¹³ The decision on isolation and restrictions should be considered as a spectrum of tailored restrictions and made after assessing pre-treatment bacterial load, efficacy of treatment, workspace risk, vulnerable family members and economic and social risk to patients, including support in terms of food, financial and housing security.^10,14

The impact of TB disease and its associated symptoms may lead to depression and anxiety for both the patient and their family. At the same time, the negative psychological impact of isolation on the patient is tremendous. The associated social stigma and TB isolation measures may further add to the distress of the patient. The newer approach to TB isolation thus focuses on synthesizing various concerns, including infection control, patient wellbeing and tailored, case-to-case assessment and decision-making, and suggests curtailing the isolation time as described above.^11–17

Conclusion

Modern isolation guidelines must aim to balance infection control and patients’ wellbeing. Education for healthcare workers who care for patients with TB on providing consistent, evidence-based infection control advice is crucial. Effective interventions incorporating the latest literature on infectiousness of TB, as well as the personal and social effects of isolation, continue to improve our understanding of how best to care for our patients and their communities.